GSK mentioned the blended Section 3 outcomes for camlipixant imply this capsule “is unlikely to remodel affected person care” in recurrent persistent cough. GSK is stopping work on this indication, a setback to a program as soon as hoped to yield a brand new blockbuster product for the corporate’s respiratory drug portfolio.
The put up GSK Drug From $2B Deal Sputters in Section 3 Check in Persistent Cough appeared first on MedCity Information.
